Hypersensitivity - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Hypersensitivity - Pipeline Review, H1 2016', provides an overview of the Hypersensitivity pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypersensitivity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypersensitivity and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Hypersensitivity - The report reviews pipeline therapeutics for Hypersensitivity by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Hypersensitivity therapeutics and enlists all their major and minor projects - The report assesses Hypersensitivity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Hypersensitivity Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hypersensitivity - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hypersensitivity pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hypersensitivity Overview 6 Therapeutics Development 7 Pipeline Products for Hypersensitivity - Overview 7 Pipeline Products for Hypersensitivity - Comparative Analysis 8 Hypersensitivity - Therapeutics under Development by Companies 9 Hypersensitivity - Therapeutics under Investigation by Universities/Institutes 10 Hypersensitivity - Pipeline Products Glance 11 Early Stage Products 11 Hypersensitivity - Products under Development by Companies 12 Hypersensitivity - Products under Investigation by Universities/Institutes 13 Hypersensitivity - Companies Involved in Therapeutics Development 14 Anacor Pharmaceuticals, Inc. 14 Eisai Co., Ltd. 15 Ensemble Therapeutics Corporation 16 F. Hoffmann-La Roche Ltd. 17 JW Pharmaceutical Corporation 18 Thesan Pharmaceuticals, Inc. 19 Hypersensitivity - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 28 AN-3485 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ARN-077 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 BD-750 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 CWF-0808 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 E-34935 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 E-35018 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Monoclonal Antibody to Inhibit CCL20 for Arthritis and Contact Hypersensitivity - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 OA-1 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Recombinant Peptide to Inhibit Calcineurin for Rheumatoid Arthritis and Hypersensitivity - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Recombinant Protein to Activate Gal-1 for Immunology - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 RN-486 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Hypersensitivity - Dormant Projects 39 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 40 Disclaimer 41
List of Tables
Number of Products under Development for Hypersensitivity, H1 2016 7 Number of Products under Development for Hypersensitivity - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Products under Investigation by Universities/Institutes, H1 2016 13 Hypersensitivity - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 14 Hypersensitivity - Pipeline by Eisai Co., Ltd., H1 2016 15 Hypersensitivity - Pipeline by Ensemble Therapeutics Corporation, H1 2016 16 Hypersensitivity - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 17 Hypersensitivity - Pipeline by JW Pharmaceutical Corporation, H1 2016 18 Hypersensitivity - Pipeline by Thesan Pharmaceuticals, Inc., H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 27 Hypersensitivity - Dormant Projects, H1 2016 39
List of Figures
Number of Products under Development for Hypersensitivity - Comparative Analysis, H1 2016 8 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products by Top 10 Targets, H1 2016 21 Number of Products by Stage and Top 10 Targets, H1 2016 21 Number of Products by Top 10 Mechanism of Actions, H1 2016 23 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 23 Number of Products by Routes of Administration, H1 2016 25 Number of Products by Stage and Routes of Administration, H1 2016 25 Number of Products by Molecule Types, H1 2016 27
Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliabRead More...
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to moRead More...
Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to driRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.